Form 4: Arcutis Biotherapeutics Director Sells Over 10,000 Shares Under Pre-Arranged Trading Plan

Howard G. Welgus, a Director at Arcutis Biotherapeutics, Inc., sold 10,139 shares of common stock for approximately $135,560 under a pre-arranged 10b5-1 trading plan.

Summary

• Howard G. Welgus, a Director of Arcutis Biotherapeutics, Inc. (ARQT), reported the sale of 10,139 shares of the company's common stock.
• The transaction occurred on June 18, 2025, at a weighted average sale price of $13.3715 per share.
• The total value of the shares sold is approximately $135,560.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Welgus on March 11, 2025, and is set to conclude on May 29, 2026.
• Following this transaction, Mr. Welgus beneficially owns 109,414 shares of Arcutis Biotherapeutics common stock.
• The shares were sold in multiple transactions within a price range of $13.2118 to $13.59.

Sentiment

Score: 4

Explanation: The sale of shares by a director, even under a 10b5-1 plan, can be viewed with slight caution by the market, though the pre-planned nature mitigates the negative signal of a reactive sale.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on immediate, undisclosed material information, which can mitigate negative market perception of insider selling.

Negatives

• A director selling a significant number of shares can sometimes be perceived negatively by investors, potentially signaling a lack of confidence or a desire to diversify holdings away from the company.

Risks

• No specific risks were mentioned in the document beyond the details of the stock transaction itself.

Future Outlook

The document indicates that the Rule 10b5-1 trading plan, under which this transaction occurred, is scheduled to continue until May 29, 2026, suggesting potential future pre-planned transactions by the reporting person.

Management Comments

• The transaction was effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry trends or competitive analysis for the biotherapeutics sector.

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret the director's sale as a signal, potentially influencing their investment decisions, although the 10b5-1 plan suggests it's not based on new, undisclosed information.

Next Steps

• The Rule 10b5-1 trading plan adopted by Howard G. Welgus is set to continue until May 29, 2026, implying potential for further pre-scheduled transactions.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, SEC Form 4, Insider Trading, Stock Sale, Director, Howard G. Welgus, 10b5-1 Plan, Common Stock